SVRA logoSVRA
Savara Inc

22,693
Loading...
Loading...
News
all
press releases
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On February 12...
Business Wire·7mo ago
News Placeholder
More News
News Placeholder
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, Long-Term Outcomes in Five Patients...
Business Wire·7mo ago
News Placeholder
Savara Announces Participation in Upcoming Healthcare Investor Conferences
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending two...
Business Wire·7mo ago
News Placeholder
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On December 20...
Business Wire·9mo ago
News Placeholder
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the...
Business Wire·9mo ago
News Placeholder
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the...
Business Wire·9mo ago
News Placeholder
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. On November 20...
Business Wire·10mo ago
News Placeholder
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal...
Business Wire·10mo ago
News Placeholder
Savara Announces Participation in Upcoming Healthcare Conferences
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the...
Business Wire·10mo ago
News Placeholder
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2024...
Business Wire·10mo ago

Latest SVRA News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.